# Haplo Peripheral Blood Sct In GVHD Prevention

> **NCT04473911** · PHASE1 · COMPLETED · sponsor: **Zachariah Michael DeFilipp** · enrollment: 25 (actual)

## Conditions studied

- GVHD
- AML
- ALL
- MDS
- MPN
- CMML
- Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- Blood Stem Cell Transplant Failure
- Graft Vs Host Disease
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Disorder
- Chronic Myelomonocytic Leukemia
- Chemosensitive Hodgkin Lymphoma

## Interventions

- **DRUG:** FLUDARABINE
- **DRUG:** CYCLOPHOSPHAMIDE
- **RADIATION:** TBI
- **DRUG:** Melphalan
- **DRUG:** Sirolimus
- **DRUG:** Mycophenolate mofetil
- **DRUG:** RGI-2001
- **DRUG:** CYCLOPHOSPHAMIDE

## Key facts

- **NCT ID:** NCT04473911
- **Lead sponsor:** Zachariah Michael DeFilipp
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-14
- **Primary completion:** 2023-10-22
- **Final completion:** 2024-08-19
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04473911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04473911, "Haplo Peripheral Blood Sct In GVHD Prevention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04473911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*